{"name":"Revance Therapeutics","slug":"revance","ticker":"RVNC","exchange":"NASDAQ","domain":"revance.com","description":"Revance Therapeutics is a biotechnology company focused on aesthetics and neurotoxin therapeutics. The company's top drugs include Daxxify, a long-acting neuromodulator for facial aesthetics. Revance Therapeutics is a leading player in the aesthetics market, with a strong pipeline of products in development. The company's products aim to provide long-lasting and effective solutions for patients seeking facial rejuvenation.","hq":"Nashville, TN","founded":0,"employees":"","ceo":"Mark Foley","sector":"Aesthetics / Neurotoxin","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$420M","metrics":{"revenue":280000000,"revenueGrowth":364,"grossMargin":0,"rdSpend":79410000,"netIncome":-323986000,"cash":478454000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2038-06-01","label":"Daxxify patent cliff ($0.0B at risk)","drug":"Daxxify","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"DAXXIFY","genericName":"DAXIBOTULINUMTOXINA-LANM","slug":"daxibotulinumtoxina-lanm","indication":"Other","status":"marketed"},{"name":"DAXI for injection 250 U","genericName":"DAXI for injection 250 U","slug":"daxi-for-injection-250-u","indication":"Glabellar lines (frown lines) in adults","status":"phase_2"},{"name":"DAXI for injection 375 U","genericName":"DAXI for injection 375 U","slug":"daxi-for-injection-375-u","indication":"Other","status":"phase_2"},{"name":"DAXXIFY","genericName":"DAXXIFY","slug":"daxxify","indication":"Other","status":"marketed"},{"name":"DaxibotulinumtoxinA for injection","genericName":"DaxibotulinumtoxinA for injection","slug":"daxibotulinumtoxina-for-injection","indication":"Glabellar lines (frown lines) for aesthetic use","status":"phase_3"}]}],"pipeline":[{"name":"DAXXIFY","genericName":"DAXIBOTULINUMTOXINA-LANM","slug":"daxibotulinumtoxina-lanm","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"DAXI for injection 250 U","genericName":"DAXI for injection 250 U","slug":"daxi-for-injection-250-u","phase":"phase_2","mechanism":"DAXI is a botulinum toxin type A formulation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.","indications":["Glabellar lines (frown lines) in adults","Cervical dystonia"],"catalyst":""},{"name":"DAXI for injection 375 U","genericName":"DAXI for injection 375 U","slug":"daxi-for-injection-375-u","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"DAXXIFY","genericName":"DAXXIFY","slug":"daxxify","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DaxibotulinumtoxinA for injection","genericName":"DaxibotulinumtoxinA for injection","slug":"daxibotulinumtoxina-for-injection","phase":"phase_3","mechanism":"DaxibotulinumtoxinA is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","indications":["Glabellar lines (frown lines) for aesthetic use","Cervical dystonia","Blepharospasm","Hemifacial spasm"],"catalyst":""}],"recentEvents":[{"date":"2023-06-06","type":"regulatory","headline":"Revance Therapeutics Announces FDA Approval of Daxxify for the Temporary Relaxation of Facial Muscles","summary":"Revance Therapeutics announced that the FDA has approved Daxxify for the temporary relaxation of facial muscles.","drugName":"Daxxify","sentiment":"positive"},{"date":"2022-11-09","type":"earnings","headline":"Revance Therapeutics Reports Third Quarter 2022 Financial Results","summary":"Revance Therapeutics reported its third-quarter 2022 financial results, with revenue of $14.4 million.","drugName":"","sentiment":"neutral"},{"date":"2022-08-09","type":"deal","headline":"Revance Therapeutics Announces Collaboration with Galderma for Daxxify","summary":"Revance Therapeutics announced a collaboration with Galderma to commercialize Daxxify in the United States.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBUTGk5NnpUUXduQmZNYUl4T0R4dzFaMmF2N0xzWU5WUHIyRjRoRE5IVjZwa2EydUEtemJWNnhVbjJ6YkFWbDR6aTVXZ3pjbk9IX200?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"RVNC Stock Price, News & Analysis - Stock Titan","headline":"RVNC Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOaC1UZm9jS1pRWjZpY0pvVUFLR0tkNXFnTHVnbDE2dzFHSnVZZkgtSUp1aE5QOWZaOXRCd3lJR244RFBZRkNmdmNDSGxmRHVoMkpmZnh0RF9WN1k5QTdrVWJoWUgzNlZVWmZITVJlNzlfaHFTaDhpbDlOcG1Gb01rMjlPNGxtZzBRVTQyY01TMnF6SjlOWko5OV9pZWNwUDFRMW44Xzd4aHMyQjNUYnVieFV3RHNrSXo5TTZKM213?oc=5","date":"2025-02-07","type":"pipeline","source":"Business Wire","summary":"Crown Laboratories Completes Acquisition of Revance Therapeutics - Business Wire","headline":"Crown Laboratories Completes Acquisition of Revance Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5UWEJuNktXSE4wZkZDTHFMVW5KMkpOR2NRRGd5OWJib2hfM1VDSmdTSm9qZ0xhZ2UyaThaTWg3WmpDbzUzZ1dtT3NXQVpUOEVLQzVGQ1pCMHNrQnVjcnFhSVM3MkdObnZjQmFLVUhTbkhoTXA5bjhyNA?oc=5","date":"2024-08-13","type":"deal","source":"The Pharma Letter","summary":"Crown Laboratories to acquire Revance - The Pharma Letter","headline":"Crown Laboratories to acquire Revance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPTi13b2EyTzl6MW5IemZ6RTNGZ3VNeW5CQUp4RHVMTnpVZTBjdjBEOXlEYVNlVGl0cUpjTjJnakYxaXVPLTJfOThIVjFxcng4N3M2bk5KLXZlbHc5WGFNc28zYkxpTUcySmRsNkRUOGI5a2hReXpxM2RLTUVqRld6RzBQX1llNWFzWVN6a3RmU2ZmZk02V3VLRU1fcmFEV3NvU3BTVWxiQkswMzU1NXc?oc=5","date":"2024-06-20","type":"pipeline","source":"Seeking Alpha","summary":"Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes (NASDAQ:RVNC) - Seeking Alpha","headline":"Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes (NASDAQ:RVNC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZGw4TUlJcjhqQVQ2NWtWUXRjTE81MXkzSVZkNk1FQ3VmMDBoakJKbGU5Wk03OFc0MGltZ1FKVzdjMDRJMDlPeXhNdjBGUkFTeEpwb0hjUVNmYVZ3cFlCWUROUzZETWFQNEVhM093b0Q1eUZfeXh0N2FjSmJ1MEdJMUV5M1BDRW5C?oc=5","date":"2024-05-12","type":"pipeline","source":"Yahoo Finance","summary":"3 Underappreciated Stocks That Could 10x in 10 Years - Yahoo Finance","headline":"3 Underappreciated Stocks That Could 10x in 10 Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNVEhHN21WMXloeEFZWlpPcHJCNVVfaUs3THVfaUFSSVJIeGhWeThKaW52RlNEcDM2LWlseW9RQXhGdUd0YzFRdTVManh6U3ZUTU1YSUtJdjVkWFVEUHJiOUNxU2RxOWtJQzVZWmJwODZpMW1WblJwc0laNExxWnRFc3NhLUZhYV9FeFJCYnJNLUg2N2pDdG5leHJxSFJzQ3VBd3AydDNKVjNVNWs1X2pwVXZrTmN2cHBkU3h3OU5MU2tWYjg1VF9GSFY0NkwxNy1WMXVDWg?oc=5","date":"2023-12-13","type":"pipeline","source":"Reuters","summary":"US consumer group seeks stronger warnings on Botox, similar treatments - Reuters","headline":"US consumer group seeks stronger warnings on Botox, similar treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOVjRzamtWVlRuMmRSdW9PTGRPTndIMWRLbXYyTTVwckJmZGkySHZqUzBPYnBPZHNIZXRUY2xZMG94aXJTTlRLRTRUNG1Ua0NnUDRoczlpOWZPRE5oNUxvY3h2enVLMTZwNEN1d0FGM3FMNjZEMXhDd2JzUHFDTXY0LXB5ZlpXZHpZVGp6V0JCQlpIZzRNTzAwQ0lPOGNrcW80QlZxSnNtVkdIek1iVGlEV1pHNUM?oc=5","date":"2022-09-08","type":"regulatory","source":"Fierce Pharma","summary":"With long-awaited FDA nod, Revance set to take on AbbVie's Botox with its longer-lasting Daxxify - Fierce Pharma","headline":"With long-awaited FDA nod, Revance set to take on AbbVie's Botox with its longer-lasting Daxxify","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPSGg4ZWIxaml4U0hvVk4zNUFBTVVsWHUxYWFmY0ZQV0w4TlM2TDVIZlBIejJWeHF0SHNES2R2aVlUM3E3QVFBWC03OURnQ1ZKWUN5SzI4UkxrZk05d2VGb1lrZkxxS2xVWmdrelNJRGRMLXBIeTl1T0QxbmMyNmJrb0R0amtIRWtaNzFfUXVn?oc=5","date":"2022-09-08","type":"regulatory","source":"Barron's","summary":"FDA Approves New Botox Competitor From Revance Therapeutics - Barron's","headline":"FDA Approves New Botox Competitor From Revance Therapeutics - Barron's","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPVERleXhNQzJQaFJnSlVZWmZta3dSZmkyeGhhc01PTXhlckU4cTFTX1B3MXdQR1BLc3lnUE9iaGsySGdRajBxVXA4QzZDb2xpQzViLXczeTJTdXM2UjVWWENyRDRMREpsTGRIYlR2V3NtNGRNX05Xd3NuZXg4WUVoeTlOdHJyNDhqZEJCaVhKSlZXa3MxMU9xYnFoVm9Td3g3WHdwQXdoZUNDazJGMjJFRUNNRDlkdk0xczhMOWk5MEp4d0pVSGpOcmlGNXJXNkNlSjVPVG5JWGF5RVhlSTAxX25LSGRyVDh3cERoNzAtb2RwY3FaNHJzUVRiMUt4WWh6RFR5d2ZRdWxwRUNhRU00WUI2cFJkUmZXWHo0?oc=5","date":"2020-12-22","type":"pipeline","source":"PR Newswire","summary":"Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection - PR Newswire","headline":"Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of Daxibotulinumtoxin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPMGUwMDF0akxHN3B1WW44eGlQeGxXQ2pnT1NsdWlOZllZRW1mbGl0SGxkX05icHREU3JRZ2xUdUhnYkxKM210Y3kwUlJxTDYtcjlxeVF3VGpXV2hUODZFMFByTjVNUV9QYXlaSHhMb1o1SXkycUN4VFVid2lvS2l0U2dTQVRkWE55Q3lzWnJnaDJNanREWW9vSFRyamVfYml4UkFzZnRKWG4?oc=5","date":"2017-12-05","type":"trial","source":"statnews.com","summary":"Revance ‘Better Botox’ wrinkle reducer scores pair of clinical trial wins - statnews.com","headline":"Revance ‘Better Botox’ wrinkle reducer scores pair of clinical trial wins","sentiment":"neutral"}],"patents":[{"drugName":"Daxxify","drugSlug":"daxibotulinumtoxina","patentNumber":"","type":"Patent Cliff","expiryDate":"2038-06-01","territory":"US","annualRevenue":0}],"drugCount":5,"phaseCounts":{"marketed":2,"phase_2":2,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merz Aesthetics","Galderma","Allergan"],"therapeuticFocus":["Aesthetics","Neurotoxin Therapeutics"],"financials":{"source":"sec_edgar+yahoo","revenue":413000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":413000,"period":"2019-12-31"},{"value":89000,"period":"2019-12-31"},{"value":46000,"period":"2019-09-30"},{"value":0,"period":"2019-06-30"},{"value":278000,"period":"2019-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":79410000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-323986000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":478454000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}